2022
Discovery of Biomarkers of Resistance to Immune Checkpoint Blockade in NSCLC Using High-Plex Digital Spatial Profiling
Moutafi M, Martinez-Morilla S, Divakar P, Vathiotis I, Gavrielatou N, Aung TN, Yaghoobi V, Fernandez AI, Zugazagoitia J, Herbst R, Schalper KA, Rimm DL. Discovery of Biomarkers of Resistance to Immune Checkpoint Blockade in NSCLC Using High-Plex Digital Spatial Profiling. Journal Of Thoracic Oncology 2022, 17: 991-1001. PMID: 35490853, PMCID: PMC9356986, DOI: 10.1016/j.jtho.2022.04.009.Peer-Reviewed Original ResearchConceptsImmune checkpoint inhibitorsICI resistanceDigital spatial profilingICI therapyOverall survivalPretreatment samplesQuantitative immunofluorescenceImmune checkpoint blockadeRole of neutrophilsShorter overall survivalCandidate biomarker proteinsCandidate protein biomarkersCohort validationOperable NSCLCUntreated NSCLCCheckpoint inhibitorsCheckpoint blockadeCD66b expressionAdditional patientsClinical efficacyPoor outcomeDiscovery of biomarkersUnivariate analysisNSCLCPatients
2013
Practice Patterns and Perceptions of Thoracic Oncology Providers on Tobacco Use and Cessation in Cancer Patients
Warren GW, Marshall JR, Cummings KM, Toll B, Gritz ER, Hutson A, Dibaj S, Herbst R, Dresler C, Committee I. Practice Patterns and Perceptions of Thoracic Oncology Providers on Tobacco Use and Cessation in Cancer Patients. Journal Of Thoracic Oncology 2013, 8: 543-548. PMID: 23529191, PMCID: PMC3628367, DOI: 10.1097/jto.0b013e318288dc96.Peer-Reviewed Original ResearchConceptsCancer patientsTobacco useOncology providersPractice patternsClinical careInitial patient visitTobacco cessation activitiesLung cancer patientsTobacco cessation methodsCessation activitiesMedication optionsCessation assistanceCessation interventionsPoor outcomeSmoking cessationTobacco cessationCessation effortsCancer careLung cancerCessation methodsAffect OutcomesPatient visitsPhysician respondentsTobacco assessmentClinician educationAssessing Tobacco Use by Cancer Patients and Facilitating Cessation: An American Association for Cancer Research Policy Statement
Toll BA, Brandon TH, Gritz ER, Warren GW, Herbst RS, Tobacco and Cancer W. Assessing Tobacco Use by Cancer Patients and Facilitating Cessation: An American Association for Cancer Research Policy Statement. Clinical Cancer Research 2013, 19: 1941-1948. PMID: 23570694, PMCID: PMC5992896, DOI: 10.1158/1078-0432.ccr-13-0666.Peer-Reviewed Original ResearchConceptsTobacco useTobacco cessationCessation interventionsEvidence-based cessation interventionsTreatment-related toxicitySecond primary tumorsTobacco cessation interventionsQuality cancer careQuality of lifeAmerican AssociationCessation assistancePoor outcomeCancer careCancer patientsPrimary tumorOncology settingCancer recurrencePatientsTreatment efficacyTreatment settingsEvidence-based proceduresCancer leadCancerCancer progressionClinical infrastructure
2012
Influence of extracapsular extension on lymph node staging for patients with squamous cell carcinoma of the head and neck.
Baumgart M, Acevedo-Gadea C, Wang Z, Buta E, Davies M, Deshpande H, Decker R, Sasaki C, Judson B, Herbst R, Morgensztern D. Influence of extracapsular extension on lymph node staging for patients with squamous cell carcinoma of the head and neck. Journal Of Clinical Oncology 2012, 30: 5532-5532. DOI: 10.1200/jco.2012.30.15_suppl.5532.Peer-Reviewed Original ResearchPoor prognostic factorSquamous cell carcinomaExtracapsular extensionOral cavityOverall survivalPrognostic factorsCell carcinomaIndependent poor prognostic factorNeck squamous cell carcinomaCox proportional hazards modelSignificant OS differenceSquamous cell cancerProportional hazards modelPrognostic impactSurveillance EpidemiologyCell cancerPoor outcomeKaplan-MeierECE statusOS differenceAJCC manualEligibility criteriaHazards modelPrimary siteSurvival curves
2003
P-484 Synchronous overexpression of epidermal growth factor receptor and HER2-NEU is a predictor of poor outcome in patients with stage I non-small cell lung cancer
Onn A, Correa A, Gilcrease M, Massarelli E, Bucana C, Hong W, Fidler I, Putnam J, Herbst R. P-484 Synchronous overexpression of epidermal growth factor receptor and HER2-NEU is a predictor of poor outcome in patients with stage I non-small cell lung cancer. Lung Cancer 2003, 41: s213. DOI: 10.1016/s0169-5002(03)92451-2.Peer-Reviewed Original ResearchTumor Cavitation Is Associated With Epidermal Growth Factor Expression and Is a Predictor of Poor Outcome in Patients With Stage I Non-Small Cell Lung Cancer
Onn A, Marom E, Isobe T, Choe D, Correa A, Putnam J, Herbst R. Tumor Cavitation Is Associated With Epidermal Growth Factor Expression and Is a Predictor of Poor Outcome in Patients With Stage I Non-Small Cell Lung Cancer. CHEST Journal 2003, 124: 102s. DOI: 10.1378/chest.124.4_meetingabstracts.102s-a.Peer-Reviewed Original Research